Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma
2007 Standout
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
2008
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
2014
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
Epithelial‐mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients
2014
LinkedOmics: analyzing multi-omics data within and across 32 cancer types
2017 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
2005
Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey
2009 Standout
Proteasome inhibitors in cancer therapy
2017
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
Autophagy and the Integrated Stress Response
2010 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Resources for mental health: scarcity, inequity, and inefficiency
2007 Standout
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Lung cancer: current therapies and new targeted treatments
2016 Standout
Combined autophagy and proteasome inhibition
2014
Genetically programmed chiral organoborane synthesis
2017 StandoutNatureNobel
The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents
2000
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
Multimodal biomedical AI
2022 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma
2013
Current treatment standards and future strategies in mantle cell lymphoma
2008
Systemic amyloidosis
2015 Standout
pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels
2014 Standout
EMT: 2016
2016 Standout
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Treatment of Relapsed/Refractory Multiple Myeloma
2009
Alternative Activation of Macrophages: Mechanism and Functions
2010 Standout
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer
2017
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
2017 Standout
Is NF-κB a good target for cancer therapy? Hopes and pitfalls
2008
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Molecular mechanisms of necroptosis: an ordered cellular explosion
2010 Standout
Targeting autophagy in cancer
2017 Standout
Applications of machine learning in drug discovery and development
2019 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Activated macrophages in the tumour microenvironment—dancing to the tune of TLR and NF‐κB
2009
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
2016
Drug resistance in cancer – searching for mechanisms, markers and therapeutic agents
2007
The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
2014
Developing new drugs for the treatment of lymphoma
2005
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib
2015
The potential of proteasome inhibitors in cancer therapy
2008
Modes of resistance to anti-angiogenic therapy
2008 Standout
The NCI60 human tumour cell line anticancer drug screen
2006 Standout
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
Protein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome Gene Expression
2019 StandoutNobel
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Interactions of tumor cells with dendritic cells: balancing immunity and tolerance
2007
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
2012 StandoutNobel
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Boron Chemicals in Diagnosis and Therapeutics
2013
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)
2006 Standout
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
2003
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
2013
Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma
2014
Regulatory T Cells and Human Disease
2020 StandoutNobel
Bendamustine: Rebirth of an Old Drug
2009
The Tumor Lysis Syndrome
2011 Standout
Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
2007
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
2015
Women with Schizophrenia and Broken Marriages - Doubly Disadvantaged? Part I: Patient Perspective
2003
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study
2011
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Cetuximab-Related Tumor Lysis Syndrome in Metastatic Colon Carcinoma
2008
Improved survival in multiple myeloma and the impact of novel therapies
2007 Standout
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration
2012 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Critical role of NF-κB in pancreatic cancer
2014
Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
2011
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma
2008
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study
2009
Multiple Myeloma
2011 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of Anthony Boral being referenced
Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture.
1998
Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?
2006
Clinical evaluation of biologically targeted drugs: Obstacles and opportunities
1998
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma
2008
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline
2009
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
2008
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
2008
Bortezomib-Induced Tumor Lysis Syndrome in Multiple Myeloma
2006
Multicenter Randomized Phase II Study of Weekly or Twice-Weekly Bortezomib Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal-Zone B-Cell Lymphoma
2009
Results of a First-In-Human Phase I Study of the Alk Inhibitor LDK378 in Advanced Solid Tumors
2012
First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors.
2012
Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.
2006
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
2014
Evaluation of Ceritinib-Treated Patients (Pts) with Anaplastic Lymphoma Kinase Rearranged (Alk+) Non-Small Cell Lung Cancer (Nsclc) and Brain Metastases in the Ascend-1 Study
2014
Phase II Clinical Study of Bortezomib (VELCADE®) in Patients (pts) with Relapsed / Refractory Non-Hodgkin’s Lymphoma (NHL) and Hodgkin’s Disease (HD).
2004
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
2006
Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity
2006
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.
2004
Family burden among long term psychiatric patients.
1995
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
2006